Multiple Sclerosis

Head-to-Head Trial Compares Low-Cost MS Drug to Brand Drug

George Padron
Neurology & Mental Health, Multiple Sclerosis, Clinical Trial Updates | Jul 8, 2026
OVERLORD-MS, the first randomized head-to-head trial, finds low-cost off-label rituximab noninferior to ocrelizumab on MRI activity in newly diagnosed relapsing MS.